PMID: 6403580Apr 1, 1983Paper

Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins

The Journal of Clinical Investigation
S I RosenfeldJ P Leddy

Abstract

Human serum lipoproteins are known to participate in or modify several immunologically relevant responses, including the inhibition of target cell lysis initiated by fluid-phase C5b-7 (reactive lysis). We now report that human high density lipoproteins (HDL) can inhibit the complement (C) lytic mechanism after C5b-7, C5b-8, and even C5b-9 have been bound to the target membrane. This inhibitory activity of serum or plasma copurifies in hydrophobic chromatography with antigenically detected apolipoprotein A-I (apoA-I), the major HDL apoprotein, and with HDL in CsCl density gradient ultracentrifugation. Although HDL is more active than its apoproteins in fluid-phase inhibition of C5b-7-initiated reactive lysis, the HDL apoproteins are more effective after C5b-7, C5b-8, or C5b-9 have become bound to human or sheep erythrocytes (E). Highly purified HDL apoproteins, apoA-I and apoA-II, both have greater inhibitory activity than whole HDL on a protein weight basis, and some evidence has been obtained that apoA-I dissociating spontaneously from HDL may be the principal inhibitory moiety in physiological situations. HDL lipids themselves are inactive. The HDL-related inhibitors are ineffective when incubated with EC5b-7 and removed befo...Continue Reading

Associated Clinical Trials

References

Aug 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·E P BendittR H Hanson
Feb 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·E R PodackH J Müller-Eberhard
Aug 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G M HänschM L Shin
Dec 1, 1981·The Journal of Experimental Medicine·G BieseckerD Koffler
Feb 4, 1982·The New England Journal of Medicine·G BieseckerD Koffler
Feb 1, 1956·Proceedings of the Society for Experimental Biology and Medicine·V I OYAMA, H EAGLE

❮ Previous
Next ❯

Citations

Jan 1, 1993·Cancer Chemotherapy and Pharmacology·K A Peck-MillerH P Fell
Jan 1, 1983·Springer Seminars in Immunopathology·U E Nydegger, M D Kazatchkine
Dec 3, 2002·Lipids·Cristiane Jaciara FurlanetoAna Campa
May 1, 1986·Molecular Immunology·K K StanleyJ P Luzio
Nov 1, 1991·Molecular Immunology·K MatsudaH Sugita
Mar 8, 2002·Atherosclerosis·Jerzy-Roch NoferArnold von Eckardstein
Mar 30, 2001·Biochimica Et Biophysica Acta·C G BrouilletteD W Borhani
Sep 8, 2011·The Journal of Biological Chemistry·Marta Biedzka-SarekMatti Jauhiainen
Apr 28, 2009·Current Opinion in Lipidology·Arnold von Eckardstein, Lucia Rohrer
Sep 2, 2011·Current Opinion in Lipidology·Giuseppe D NorataAlberico L Catapano
Feb 23, 2013·Journal of Lipids·Hidesuke Kaji
Sep 18, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Andrew N HoofnagleJay W Heinecke
Jun 1, 1984·The Journal of Clinical Investigation·R TerkeltaubM H Ginsberg
Feb 24, 2007·Vascular Health and Risk Management·Giuseppe D Norata, Alberico L Catapano
May 6, 2005·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A L PasquiM Pastorelli
Jul 26, 2011·Atherosclerosis·Giuseppe Danilo NorataAlberico Luigi Catapano
May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·R W JamesD Hochstrasser
May 31, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nathalie NiyonzimaTerje Espevik
Apr 26, 2020·Biomolecules·Bjorn Kaijun BetzlerChing-Yu Cheng
Nov 25, 2020·International Journal of Molecular Sciences·Vasily A KudinovSergey S Markin
Jan 1, 1986·Journal of Cellular Biochemistry·E R Podack

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.